SYS6023

SYS6023 is an antibody-drug conjugate developed by CSPC Megalith Biopharmaceutical. Its target is HER3 (the sponsor names HER3). The sponsor states: Antibody-drug conjugate targeting HER3, administered by intravenous infusion. ClinicalTrials.gov describes the intervention as: SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in HR-positive / HER2-negative breast cancer. The largest, NCT07597629, plans to enrol 36 participants with primary completion expected 2027-11-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.